Using Predictable And Efficient Data To Take The Risk Out Of Site Selection
By Michelle Yu, Associate Director, Total Feasibility Services, WCG, with contribution from Priyanka Bhatt, Director, Clinical Data Scientist, WCG, and Elizabeth Lanphear, Clinical Data Analyst, WCGSummary
Sponsors and CROs need to reduce trial risk and increase reliability. They also need to make the most of their study start-up budget. To accomplish this, they need to select qualified sites that consistently optimize enrollment, ensure data quality, and maximize ROI.
These things are evident to anyone who’s spent a day in our industry. But what’s less obvious is how they find these qualified sites.
The solution: Data, wisely used. The conventional scattershot way of identifying sites is unpredictable and costly. In contrast, applying data and data analytics to the site-identification process makes the process much more predictable. Specifically, with WCG’s proprietary intelligence, sponsors can predictably increase study-enrollment performance.
We’ve seen this with our clients, of course. But would this work on other trials?
We decided to find out.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.